MBRX Moleculin Biotech, Inc.

1.52
+0.42  (38%)
Previous Close 1.10
Open 1.25
Price To book 1.21
Market Cap 26.99M
Shares 17,756,000
Volume 5,544,160
Short Ratio 4.31
Av. Daily Volume 716,794

SEC filingsSee all SEC filings

  1. 8-K - Current report 17909462
  2. 8-K - Current report 17881456
  3. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 17864201
  4. 8-K - Current report 17864070
  5. 8-K - Current report 17858655

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 data due 2018.
Annamycin
Acute myeloid leukemia (AML) - cancer

Latest News

  1. Biotech Stocks Showing Signs of Resurgence
  2. Moleculin Announces Scientific Support for Research Endeavor at Mayo Clinic
  3. Biotech Industry Showing Signs of a Revival in 2017: Today's Research on Moleculin Biotech and Merrimack Pharmaceuticals
  4. Moleculin Announces Significant Discovery with Potential to Treat Pancreatic Cancer
  5. Moleculin Announces Intent to Expand Annamycin Planned Clinical Trial to Include Sites in Poland
  6. Moleculin Announces Preparation to File an IND with the FDA for WP1220 for Treatment of Cutaneous T-Cell Lymphoma
  7. Moleculin Biotech to Present at Upcoming Investor Conferences
  8. Moleculin Biotech Issues Shareholder Update on FDA Designation of Orphan Drug and IND Status for Annamycin
  9. Moleculin Biotech, Inc. Reports Financial Results for the First Quarter Ended March 31, 2017
  10. Moleculin Biotech to Present at Joseph Gunnar & Co. PIONEERS 2017 Conference
  11. Moleculin Biotech Appoints Theradex Systems as CRO to Manage Phase I/II Annamycin Trial
  12. Moleculin Biotech, Inc. Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016
  13. Orphan Drug Status and Investor Confidence Boost Stock Prices of Moleculin Biotech and Innocoll Holdings
  14. Moleculin Leukemia Drug Gets Orphan Drug Status
  15. Moleculin Receives Orphan Drug Designation for Annamycin for the Treatment of Acute Myeloid Leukemia
  16. Moleculin to Present at the 29th Annual Roth Capital Conference
  17. Moleculin Announces Pricing of $5 Million Underwritten Public Offering
  18. Moleculin Announces Expanded Scientific Advisory Board
  19. Moleculin Presents Preclinical Data of Novel Inhibitor of Glycolysis at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
  20. A Cascade Of Corporate Exec Hires This Week

SEC Filings

  1. 8-K - Current report 17909462
  2. 8-K - Current report 17881456
  3. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 17864201
  4. 8-K - Current report 17864070
  5. 8-K - Current report 17858655
  6. 8-K - Current report 17846916
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 17839120
  8. DEF 14A - Other definitive proxy statements 17795305
  9. PRE 14A - Other preliminary proxy statements 17767610
  10. 8-K - Current report 17764850